ZA96398B - 2,9-Disubstituted purin-6-ones - Google Patents

2,9-Disubstituted purin-6-ones

Info

Publication number
ZA96398B
ZA96398B ZA96398A ZA96398A ZA96398B ZA 96398 B ZA96398 B ZA 96398B ZA 96398 A ZA96398 A ZA 96398A ZA 96398 A ZA96398 A ZA 96398A ZA 96398 B ZA96398 B ZA 96398B
Authority
ZA
South Africa
Prior art keywords
ones
disubstituted purin
purin
disubstituted
Prior art date
Application number
ZA96398A
Other languages
English (en)
Inventor
Ulrich Niewoehner
Erwin Bischoff
Helmuth Schuetz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA96398B publication Critical patent/ZA96398B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
ZA96398A 1995-01-19 1996-01-18 2,9-Disubstituted purin-6-ones ZA96398B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
ZA96398B true ZA96398B (en) 1996-08-28

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96398A ZA96398B (en) 1995-01-19 1996-01-18 2,9-Disubstituted purin-6-ones

Country Status (31)

Country Link
US (1) US5861404A (xx)
EP (1) EP0722944A1 (xx)
JP (1) JPH08231545A (xx)
KR (1) KR960029334A (xx)
CN (1) CN1135485A (xx)
AR (1) AR002953A1 (xx)
AU (1) AU4097996A (xx)
BG (1) BG61728B1 (xx)
BR (1) BR9600147A (xx)
CA (1) CA2167353A1 (xx)
CO (1) CO4700523A1 (xx)
CZ (1) CZ16696A3 (xx)
DE (1) DE19501482A1 (xx)
EE (1) EE9600018A (xx)
FI (1) FI960225A (xx)
HR (1) HRP960007A2 (xx)
HU (1) HUP9600106A3 (xx)
IL (1) IL116769A (xx)
MA (1) MA23778A1 (xx)
NO (1) NO960223L (xx)
NZ (1) NZ280830A (xx)
PE (1) PE64996A1 (xx)
PL (1) PL312354A1 (xx)
SG (1) SG50401A1 (xx)
SK (1) SK8096A3 (xx)
SV (1) SV1996000006A (xx)
TN (2) TNSN96007A1 (xx)
TR (1) TR199600028A2 (xx)
TW (1) TW314519B (xx)
YU (1) YU1396A (xx)
ZA (1) ZA96398B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6310070B1 (en) * 1997-07-15 2001-10-30 Japan Energy Corporation Purine derivatives and medicinal use thereof
WO1999024432A1 (en) * 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Purine derivatives and medicine containing the same as the active ingredient
EP1054012B1 (en) * 1998-01-05 2003-06-11 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6660745B1 (en) * 1999-05-11 2003-12-09 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
US7927623B2 (en) * 2001-02-15 2011-04-19 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
BG61728B1 (bg) 1998-04-30
NO960223L (no) 1996-07-22
TNSN96006A1 (fr) 2005-03-15
FI960225A (fi) 1996-07-20
PE64996A1 (es) 1997-03-09
TR199600028A2 (tr) 1996-08-21
SV1996000006A (es) 1996-10-29
CN1135485A (zh) 1996-11-13
CO4700523A1 (es) 1998-12-29
NO960223D0 (no) 1996-01-18
FI960225A0 (fi) 1996-01-17
NZ280830A (en) 1998-04-27
EP0722944A1 (de) 1996-07-24
AU4097996A (en) 1996-07-25
CA2167353A1 (en) 1996-07-20
HRP960007A2 (en) 1998-02-28
HUP9600106A3 (en) 1998-04-28
MA23778A1 (fr) 1996-10-01
TW314519B (xx) 1997-09-01
AR002953A1 (es) 1998-05-27
US5861404A (en) 1999-01-19
SK8096A3 (en) 1996-08-07
PL312354A1 (en) 1996-07-22
EE9600018A (et) 1996-08-15
CZ16696A3 (en) 1996-08-14
TNSN96007A1 (fr) 2005-03-15
KR960029334A (ko) 1996-08-17
IL116769A (en) 1998-12-06
BG100292A (bg) 1996-07-31
IL116769A0 (en) 1996-05-14
HU9600106D0 (en) 1996-03-28
YU1396A (sh) 1999-03-04
HUP9600106A2 (en) 1997-05-28
DE19501482A1 (de) 1996-07-25
BR9600147A (pt) 1998-01-06
JPH08231545A (ja) 1996-09-10
SG50401A1 (en) 1998-07-20

Similar Documents

Publication Publication Date Title
DE59403259D1 (en) Tetraaroxyperylen-3,4,9,10-tetracarbonsäurepolyimide
GR3033254T3 (en) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
ZA96398B (en) 2,9-Disubstituted purin-6-ones
MX213417B (es) Fenilpiridazinonas.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA95462B (en) Substitute 1,2,3,4-tetrahydro -5-nitro-pyrimidines
GR3030863T3 (en) 2',5'-oligoadenylate-2',3'-cyclophosphates
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA946569B (en) 1,5-Diphenyl-3-pyrazolylalkyl-N-hydroxydithiocarbamates
ZA969625B (en) 25-Hydroxy-16-ene-26, 27-bishomo-cholecalciferols
GB9622283D0 (en) 3,4,5-Trifluorophenyl 4- cyclohexylbenzoates
ZA966399B (en) Endothelin-receptor-antagonists.
GB9507199D0 (en) Leaflets
DE69637797D1 (en) Ten)phenylazoresorcinolen
GB9513818D0 (en) 7,7-Disubstituted cephem-4-ketones
ZA948311B (en) 1,2-dihydro-2-oxo-pyridines
IL110556A0 (en) 7 alpha-amino-1, 1-dioxocephem l- valylamides
GB2303409A8 (en) Turbine
GB2300675B (en) Turbines
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols
ZA947884B (en) 1,2-dihydro-2-oxo-3-methylsulfonylaminomethylpyridines
GB9523183D0 (en) Turbines
HK1016577A1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols